ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1543

Epidemiology and Disease Burden of Hospitalized Children with Paediatric Multisystem Inflammatory Syndrome Temporally Associated with SARS-CoV-2 Infection in Canada: A Canadian Pediatric Surveillance Program National Prospective Study

Tala El Tal1, Marie-Paule Morin2, Shaun Morris3, Roberta Berard4, Daniel Farrar5, Fatima Kakkar6, Charlotte Moore-Hepburn7, Elie Haddad2, Rosie Scuccimarri8 and Rae Yeung9, 1University of Toronto/Hospital for Sick Children, Toronto, ON, Canada, 2CHU Sainte-Justine, Montréal, QC, Canada, 3Centre for Global Child Health, The Hospital for Sick Children, Division of Infectious Diseases, The Hospital for Sick Children, Toronto; Clinical Public Health, Dalla Lana School of Public Health, University of Toronto, Toronto, Toronto, ON, Canada, 4London Health Sciences Centre, London, ON, Canada, 5Centre for Global Child Health, The Hospital for Sick Children, Toronto, ON, Canada, 6Division of Infectious Diseases, CHU Sainte-Justine, Montréal, QC, Canada, 7Division of Paediatric Medicine, Hospital for Sick Children, Toronto, ON, Canada, 8McGill University/Montreal Children's Hospital, Montréal, QC, Canada, 9The Hospital for Sick Children, Toronto, ON, Canada

Meeting: ACR Convergence 2021

Keywords: COVID-19, Kawasaki disease, MIS-C, PIMS

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 9, 2021

Title: Infection-related Rheumatic Disease Poster (1530–1564)

Session Type: Poster Session D

Session Time: 8:30AM-10:30AM

Background/Purpose: As of May 2021, Canada had reached over 1.3 million confirmed cases of SARS-CoV-2 infection, and over 25,000 deaths. This study identified children in Canada hospitalized with paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 infection (PIMS), also known as multisystem inflammatory syndrome in children (MIS-C), and aimed to 1) Describe clinical and laboratory features at presentation, management, outcomes, and 2) Identify risk factors for intensive care unit (ICU) admission.

Methods: We conducted a national prospective study using the infrastructure of the Canadian Paediatric Surveillance Program (CPSP), a network of >2,800 paediatricians across Canada. Physicians reported cases of hospitalized children who met study criteria from March 2020-May 2021, through a weekly online questionnaire distributed via the CPSP network. Cases were categorized as confirmed MIS-C, presumed MIS-C, and/or confirmed PIMS defined in Figure 1. Modified Poisson regression analysis was used to compute adjusted risk ratios (aRR) for ICU risk factors associated with PIMS/MIS-C.

Results: A total of 506 cases of children hospitalized with PIMS/MIS-C were reported during the study period, of which 383 unique cases were included in the primary analysis (161 confirmed MIS-C, 202 presumed MIS-C, and/or 352 confirmed PIMS) with the majority of cases being reported from the provinces of Ontario (44.6%) and Quebec (39.7%). A total of 167/383 (43%) cases had a SARS-CoV-2 link (62.3% close contact, 58.1% positive PCR, 32.3% known positive serology). Of the 216 cases (56%) with no known link, 55/114 with serology results available were negative. Majority were preschool (1-5 years) or school aged (6-12 years), with slight male predominance (57.7%), and were previous healthy (60 (15.7%) with co-morbidities). Median duration of fever was 6 days; 283/383 (74%) had gastrointestinal involvement; more than half had mucocutaneous changes including rash (64.5%), bilateral non-exudative conjunctivitis (62.9%), and changes in lips/oral cavity (58.7%). Laboratory features indicated hyperinflammation (Table 1).

Shock/hypotension was reported in 125 (32.6%). There were no deaths. Cardiac involvement with abnormal echocardiograms was reported in 161/366 (44%) including decreased heart function (14.5%), coronary dilatation (9.1%) and aneurysms (13.1%). Almost one third (28.5%) required ICU admission, with 25.1% requiring respiratory/hemodynamic support. For treatment, 235 (61%) received both IVIG and corticosteroids, 111 (29%) received IVIG only, 7 (1.8%) received corticosteroids only, 30 (7.8%) received neither, and 18 (4.7%) received biologics. Risk factors for ICU admission included presence of SARS-CoV-2 link (aRR 2.79, 95% CI 1.79-4.35; p < 0.001) and older age groups: school aged (aRR 2.76, 95% CI 1.71-4.46; p < 0.001) and adolescents (13-17 years) (aRR 3.00, 95% CI 1.81-4.98; p < 0.001); while no association found with sex or comorbidity (Table 2).

Conclusion: This national prospective study reports on the largest series of children hospitalized with PIMS/MIS-C in Canada, providing insight on overall severity and at–risk groups that is essential for prompt recognition and management.

Figure 1. Flow chart of participants meeting the case definitions for MIS-C and PIMS. Confirmed MIS-C: meets MIS-C criteria (adapted by the World Health Organization (WHO))a AND no other cause identified AND SARS-COV_2 link present (defined as a history of positive PCR, rapid test, or serology or close contact with microbiologically confirmed SARS-CoV_2 infection); Presumed MIS-C: same as confirmed MIS-C except no known SARS-CoV_2 link; Confirmed PIMS: meets study criteria (1) fever ≥3 days (2) elevated inflammatory markers (C-reactive protein (CRP) ≥ 30 mg/L, Erythrocyte sedimentation rate (ESR) ≥ 40 mm/h OR Ferritin ≥ 500 μg/L) (3) one or both: features of Kawasaki disease or toxic shock syndrome AND (4) no other cause identified. a https://www.who.int/news-room/commentaries/detail/multisystem-inflammatory-syndrome-in-children-and-adolescents-with-covid_19 1Of confirmed PIMS cases, 150 also met criteria for confirmed MIS-C, 182 also met criteria for presumed MIS-C, while 20 did not meet criteria for MIS-C. Six cases met criteria for confirmed or presumed MIS-C but not confirmed PIMS.


Disclosures: T. El Tal, None; M. Morin, Sobi, 1; S. Morris, Pfizer, 5, Pfizer, 1, Glaxosmithkline, 6; R. Berard, Sandoz, 2, SOBI, 2, Roche, 2; D. Farrar, None; F. Kakkar, None; C. Moore-Hepburn, None; E. Haddad, None; R. Scuccimarri, Novartis, 1, Bristol Myers Squibb, 5; R. Yeung, None.

To cite this abstract in AMA style:

El Tal T, Morin M, Morris S, Berard R, Farrar D, Kakkar F, Moore-Hepburn C, Haddad E, Scuccimarri R, Yeung R. Epidemiology and Disease Burden of Hospitalized Children with Paediatric Multisystem Inflammatory Syndrome Temporally Associated with SARS-CoV-2 Infection in Canada: A Canadian Pediatric Surveillance Program National Prospective Study [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/epidemiology-and-disease-burden-of-hospitalized-children-with-paediatric-multisystem-inflammatory-syndrome-temporally-associated-with-sars-cov-2-infection-in-canada-a-canadian-pediatric-surveillance/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/epidemiology-and-disease-burden-of-hospitalized-children-with-paediatric-multisystem-inflammatory-syndrome-temporally-associated-with-sars-cov-2-infection-in-canada-a-canadian-pediatric-surveillance/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology